Denis Vladimirovich Zaslavsky

Emollients are the fastest-growing class of cosmeceuticals. This is due to the growing number of patients with conditions requiring constant skin care, accompanied by epidermal barrier dysfunction and inflammation (e.g., xerosis, atopic dermatitis, psoriasis, seborrheic dermatitis). Nevertheless, diagnosis and management of patients with xerosis cutis remain poorly standardized. Modern studies have deepened our knowledge of the molecular composition within a multifaceted understanding of the epidermal barrier as an integral system. This has enabled the introduction of numerous active ingredients into cosmeceuticals to deliver anti-inflammatory, antioxidant, antimicrobial, and antipruritic effects. In recent years, a new approach to the treatment of dermatoses accompanied by xerosis, based on the use of so-called «emollients plus», has been developed. A new class of «smart» emollients, known as immunolents, has been identified. These products are capable of supporting the skin microbiome and skin immunity. An ideal emollient should provide adequate hydration of the stratum corneum and form a barrier that prevents transepidermal water loss. The development and regular use of moisturizers with active ingredients can provide a so-called steroid-sparing effect and reduce dependence on topical corticosteroids.

Objective. To present a new method of physiotherapeutic treatment for children with atopic dermatitis in the exacerbation stage. Material and Methods. One hundred eighty-four patients (aged 5-12) with moderate atopic dermatitis in the acute stage (SCORAD 33.46±7.27 points) were included. The study group (n=92) received physiotherapy, including green and red light photochromotherapy, in addition to standard therapy. The comparison group (n=92) received inpatient treatment according to clinical guidelines. Results. After the therapy, there was a regression of subjective and objective indicators in patients of the main group: reduction of itching, improvement of sleep and psychoemotional state, significant improvement in the quality of life of children and their families according to the quality of life questionnaires (CDLQI and FDLQI); improvement of skin status (reduction of inflammatory manifestations, regression of papular elements of the rash, reduction in the degree of lichenification and manifestations of xerosis, absence of fresh rashes), a significant decrease in the SCORAD index after this type of therapy (12.41 ± 4.19 points). Conclusions. A course of photochromotherapy in children suffering from atopic dermatitis and placed in a dermatology hospital contributes to the achievement of more significant sustainable positive clinical results, as evidenced by subjective data and objective indicators. The inclusion of a new method of photochromotherapy, using green light applied to the neck and collar area and red light applied to two or three of the most affected skin areas, in the complex therapy of children with moderate atopic dermatitis expands the potential of physiotherapy for these patients as an effective and safe method in pediatric practice.

The aim of the study was to evaluate the efficacy and tolerability of PUVA therapy in patients with extensive psoriasis vulgaris at the site of the SBHI Leningrad Regional Centre. The objectives of the study included: assessment of the clinical and functional status, psychoemotional status, and quality of life of patients with psoriasis vulgaris; assessment of incidence and nature of immediate adverse effects occurring in the course of PUVA therapy; and substantiation of feasibility of PUVA therapy for psoriasis vulgaris in the in-patient setting. The study demonstrated efficacy of PUVA therapy in patients with psoriasis vulgaris based on clinical signs using the PASI index measured in percentage. Material and methods. 20 patients with extensive psoriasis vulgaris were evaluated with the average age of 34 years and average disease duration of 10 years. All patients were randomized into 2 clinically comparable groups. The first (control) group consisted of 10 patients receiving conventional medication therapy. The second (main) group included 10 patients who received standard medication therapy and PUVA therapy provided using the PUVA-54 ultraviolet device, medical device registration certificate No. РЗН 2014/1434 dated 20 March 2024. The following examination methods were used: standard clinical and laboratory tests, instrumental examination (ultrasound examination of the abdominal organs); Psoriasis Area and Severity Index (PASI), «Prurindex» pruritus index, Dermatology Life Quality Index (DLQI), and Spielberger-Khanin anxiety scale score were calculated. Results. Clinical improvement was registered in the PUVA group — a 52 % decrease in the PASI values (PASI 52); PASI decrease in the control group made up 37 % (PASI 37), which is consistent with a minor clinical improvement; localized skin itch persisted in 6 (30 %) patients. Conclusion: Feasibility of PUVA therapy in a daycare hospital setting has been confirmed within the specialty of dermatovenereology. PUVA therapy is recommended for patients resistant to the standard methods of medication therapy including systemic and topical agents and for patients under 60 years of age, with no decompensated somatic diseases, with no general contraindications to physiotherapy, and with Fitzpatrick skin phototype II-IV.

Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This paper provides the results of the first 12-week period of phase III BCD-085-16/PLANETA-KIDS clinical study. Objective. The aim of the BCD-085-16/PLANETA-KIDS is to evaluate netakimab efficacy and safety in pediatric patients 6+ years old with moderate-to-severe plaque psoriasis. Methods. BCD-085-16/PLANETA-KIDS (NCT06640517) is a randomized, double-blind, placebo-controlled phase III clinical study with open-label active-comparator arm (adalimumab). A total of 155 male and female patients aged from 6 to 18 years with confirmed moderate-to-severe plaque psoriasis were randomized to receive netakimab (n = 83), placebo (n = 35), or adalimumab (n = 37). Netakimab dosage was weight adjusted: for patients weighing 50 kg or more netakimab dose was 120 mg (two injections of 60 mg/ml each), for patients weighing less than 50 kg netakimab dose was 60 mg (one injection of 60 mg/ml). Patients in the Netakimab group received netakimab subcutaneously once per week for the first three weeks (induction) and once every 4 weeks thereafter (maintenance). Patients in the Placebo group received placebo in blinded manner like netakimab. Adalimumab was administered in open-label way in doses recommended by the product’s SmPC. In this study co-primary efficacy endpoints were the proportion of patients achieving PASI75 and sPGA0/1 at week 12. Results. Netakimab has shown superiority over placebo for both co-primary endpoints. The proportion of patients achieving PASI75 at week 12 was 89.2% in the Netakimab group and 14.3% in the Placebo group, odds ratio (OR) 59.0, 95% CI [16.5; 211.5] (p < 0.0001). The proportion of patients achieving sPGA0/1 at week 12 was 83.1% in the Netakimab group and 8.6% in the Placebo group, OR 54.9, 95% CI [14.6; 206.5] (p < 0.0001). The subgroup analysis has shown consistent netakimab superiority over placebo for both co-primary endpoints, regardless of age, body weight and psoriasis severity. Throughout the 12-week period netakimab has shown favorable safety profile comparable to that in the Placebo group. Conclusion. The results of the 12-week period in the BCD-085-16/PLANETA-KIDS study have shown high efficacy of netakimab compared with placebo with favorable safety profile in children aged 6 years and older and adolescents with moderate-to-severe plaque psoriasis.

Ихтиозы — генетические заболевания, характеризующиеся генерализованной сухостью кожи, шелушением и гиперкератозом, нередко сопровождающиеся эритродермией. Согласно итогам консенсусной конференции по ихтиозу 2009 г. различают синдромальные и несиндромальные формы заболевания. Аутосомно-рецессивный врожденный ихтиоз относится к несиндромальным формам ихтиоза. Клинически аутосомно-рецессивный врожденный ихтиоз подразделяется на три основных фенотипа: ихтиоз Арлекина, пластинчатый (ламеллярный ихтиоз) и врожденная ихтиозиформная эритродермия. Реже встречаются менее распространенные формы: самоизлечивающийся коллоидный ихтиоз, акроакральный самоизлечивающийся коллоидный ихтиоз и ихтиоз по типу «купального костюма». Одним из наиболее легких вариантов аутосомно-рецессивного врожденного ихтиоза является ихтиоз по типу «купального костюма», который характеризуется шелушением кожи с локализацией преимущественно на туловище без поражения конечностей и лица. Заболевание вызвано чувствительными к температуре вариантами трансглутаминазы 1, кодируемой геномTGM1. Описано клиническое наблюдение ребенка трех месяцев с аутосомно-рецессивным врожденным ихтиозом по типу «купального костюма». Пациент родился недоношенным с универсальным поражением кожи по типуколлоидной пленки, которая отшелушилась в течение 10 дней. Из родильного дома новорожденного перевели Детскую городскую больницу № 1. Системную терапию ребенку не проводили, наружно применяли мазь с декспантенолом. При генетическом обследовании у мальчика выявили ранее не описанный как патогенный вариант мутации в экзоне 3 генаTGM1.В возрасте трех месяцевродители ребенка обратилисьв консультативно-диагностический центр Санкт-Петербургского государственного педиатрического медицинского университета, при его осмотре обратили внимание на своеобразную картину поражения кожи. Старшая сестра пациента также страдает врожденным ихтиозом с характерной локализацией поражения кожи на туловище и волосистой части головы. Продолжение поиска новых этиологических факторов аутосомно-рецессивного врожденного ихтиоза расширит наше понимание как патогенеза ихтиоза, так и может быть полезно с точки зрения поиска новых терапевтических подходов к лечению этого заболевания. Ichthyoses are genetic diseases characterized by generalized dry skin, scaling, and hyperkeratosis, often accompanied by erythroderma. According to the 2009 Consensus Conference on Ichthyosis, syndromic and nonsyndromic forms of the disease are distinguished. Autosomal recessive congenital ichthyosis belongs to a nonsyndromic form of ichthyosis. Clinically, autosomal recessive congenital ichthyosis is divided into three main phenotypes. The primary phenotypes are harlequin ichthyosis, lamellar ichthyosis, and congenital ichthyosis form erythroderma. Less common forms include self-limiting colloid ichthyosis, acroacral self-limiting colloid ichthyosis, and “bathing suit” ichthyosis. One of the mildest forms of autosomal recessive congenital ichthyosis is “bathing suit” ichthyosis, characterized by peeling skin localized primarily on the trunk, excluding the extremities and face. The disease is caused by temperature-sensitive variants of transglutaminase 1, encoded by theTGM1gene. We report our clinical observation of a 3-month-old child with autosomal recessive congenital ichthyosis of the “bathing suit” type. Our patient was born prematurely with a universal skin lesion resembling a “colloidal”membrane, which peeled off within 10 days. From the maternity hospital he was transferred to the Children's City Hospital No. 1. The child did not receive systemic therapy; topical treatment with dexpanthenol ointment was applied. Genetic testing revealed a previously undescribed pathogenic mutation in exon 3 of theTGM1gene. The patient's older sister also suffers from congenital ichthyosis with a characteristic localization. At the age of 3 months, the child came to the Clinical and Diagnostic Center of the Saint Petersburg State Pediatric Medical University. During his examination, a peculiar picture of skin...

Crusted scabies is a highly contagious form of scabies, most often diagnosed in patients with immunodeficiency, peripheral sensory impairment, and cognitive impairment, especially in residential social service settings. The problem is particularly relevant due to the high risk of nosocomial outbreaks and the spread of infection among contacts and staff of institutions where a patient with crusted scabies is identified. The clinical presentation of the disease is nonspecific, complicating timely diagnosis and complicating its course. A clinical analysis of crusted scabies in a patient with Down syndrome revealed typical manifestations of crusted scabies: mild itching, hyperkeratotic crusts, scalp lesions, and nail changes. The diagnosis of crusted scabies was confirmed by identifying the mite during microscopic examination of a skin scraping and by histological examination of a skin biopsy from the lesion. Treatment consisted of topical antiparasitic and keratolytic agents, as well as a range of preventive measures, which resulted in the patient's recovery. It is important to note that patients at risk for developing crusted scabies include those with immunodeficiency, impaired peripheral sensitivity, drug addiction, long-term use of hormonal and cytostatic drugs, the elderly, and those with significant comorbidities (especially cardiovascular and endocrine diseases). Timely diagnosis and implementation of a full range of medical and non-medical measures to treat scabies and prevent its spread are the foundation of care for this group of patients.

The aim. To evaluate the efficacy and safety of the double-stranded RNA sodium salt drug RADAMIN®VIRO (lyophilisate) in everyday practice with men and women having genital herpes and/or chronic urogenital chlamydial infection. Materials and methods . A multicenter observational non-randomized clinical trial was performed. The study included records of 2 714 patients: 488 patients suffering from chlamydia or a combined infection, 2 226 individuals with a confirmed diagnosis of herpes infection, of both sexes, aged over 18 years, who met the inclusion/exclusion criteria and for whom the attending physician prescribed a course of treatment with RADAMIN®VIRO as part of complex therapy prior to inclusion in this study. The efficacy of the drug was assessed during the course of treatment (as part of complex therapy for genital herpes/chronic urogenital chlamydial infection) in relation to: dynamics of symptoms (objective and subjective); speed of regression of clinical manifestations of the infection; frequency of relapses during the observation period; duration of the inter-relapse period; dynamics of quality of life according to the “Dermatological Quality of Life Index” questionnaire; and the safety of the drug was assessed. Results . It was shown that as early as day 14 of observation (visit B2), the proportion of patients with low severity or absence of subjective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 86.62–91.65 %; the proportion of patients with the absence of objective symptoms characteristic of chlamydial, herpetic, or combined infection increased to an average level of 87.09–99.69 %. It was shown that by day 7 of observation, the severity of subjective symptoms decreased from 1.27–1.72 to 0.39–0.55 in group A56 (chlamydia or combined infection), and in group A60 (herpes), it also decreased from 1.45–1.63 to an average level of 1.21–1.30; by day 14 of observation — in 32.9 % of patients, by day 90 of observation — in 1.2 % of patients, by day 180 of the study — in 0.7 % of patients. Thus, recovery occurred within 3 months from the start of therapy and observation in 99.3 % of patients — all study participants ( p < 0.001). Conclusion. Based on the obtained data, a conclusion can be drawn regarding the efficacy, safety, and appropriateness of including RADAMIN®VIRO in the complex therapy for patients with genital herpes and urogenital chlamydial infection.

This publication has been prepared following a meeting of the Council of Experts in dermatovenereology, held on February 20, 2026, in Moscow. The Council was attended by leading Russian specialists from relevant university departments and research institutes: professors M.R. Rakhmatulina, L.S. Kruglova, A.N. Lvov, K.N. Monakhov, E.V. Sokolovskiy, O.B. Tamrazova, O.I. Letiaeva, I.L. Shlivko, I.O. Smirnova, M.M. Kokhan, and D.V. Zaslavsky. The primary aim of the meeting was to perform a complex analysis of preclinical and clinical data concerning medical devices (cream, spray, lotion) containing a combination of synthetic tannin and polidocanol. The experts assessed the pharmacological properties of the ingredients and their impact on the key pathogenic aspects of itching in atopic dermatitis, eczema, and contact dermatitis. A detailed consideration was given to the results of clinical trials, including protocols with patients across various age groups (from 1 month to 94 years), in particular special populations: children and adolescents, elderly, pregnant women. Particular attention was given to analyzing the current Clinical Guidelines (2024) and identifying a therapeutic gap in targeted topical antipruritic therapy for patients with various dermatoses. The resolution provides a scientific rationale for the inclusion of products containing a combination of synthetic tannin and polidocanol in the current Clinical Guidelines and proposes specific wordings to supplement the sections concerning topical therapy. The document concludes that the combination of synthetic tannin and polidocanol has a high safety profile and proven efficacy in relieving itching, healing acute inflammatory oozing lesions, boosting the skin barrier, and improving the quality of life in patients with pruritic dermatoses.

During an interdisciplinary advisory board held in Moscow last year, experts have performed a comprehensive review concerning the problem of diaper dermatitis, the most common condition that somehow worsens the quality of life of individuals using diapers, both in adult patients and infants, including premature newborns. Discussion implicated epidemiologal and etiological issues, as well as approaches to treatment and prevention. Experts have agreed that the basis for both the prevention and treatment of diaper dermatitis is a set of measures called ABCDE, with a special focus on protecting the skin in the area under the diaper using barrier agents (B) containing 5% dexpanthenol as an active ingredient to maintain the epidermal barrier function, moisturize the skin and exert an anti-inflammatory effect. To create a strong semi-exclusive barrier on the skin under the diaper, a dexpanthenol 5% ointment with a 25% lanolin content can be successfully used, as it meets the requirements for an optimal diaper product and is a well-studied effective and safe medication with high preventive and therapeutic potential.

The article presents the main stages in the study of Devergie disease (pityriasis rubra pilaris)―from the first mentions in the works of 19th-century dermatologists to modern concepts of its etiology and pathogenesis. The earliest descriptions of the disease are found in the works by T. Bateman (1815), C. Tarral (1835), and A. Devergie (1856), who laid the foundation for the clinical understanding of this rare papulosquamous dermatosis. Further contributions to the study of the disease were made by F. Hebra, E. Besnier, M. Kaposi, and Russian researchers including V.F. Burgsdorf, who systematized the clinical features and substantiated the independence of this condition. A significant step in the study of Devergie disease was associated with the development of concepts about its possible association with vitamin A metabolism disorders and hereditary factors, as reflected in the publications of the 20th century. At the same time, the first classification was proposed by W. Griffiths. A new stage began with the introduction of molecular-genetic technologies, particularly the discovery of CARD14 mutations and the involvement of the NF-κB and MAPK signaling pathways, as well as the IL-1β/CCL20 and IL-23/IL-17A axes, which made it possible to consider the disease as an autoinflammatory dermatosis and explained the effectiveness of modern genetically engineered biological therapies. In addition, new clinical subtypes of the disease have been identified, including facial discoid dermatitis, HIV-associated, paraneoplastic, postinfectious, and CAPE subtypes. Despite significant progress in understanding the pathogenesis and the availability of modern therapeutic options, Devergie disease remains difficult to diagnose and requires further research to clarify its nosological nature and develop personalized treatment approaches.